Nephrology

Tallness linked to increased risk of premature death for patients on dialysis

 

  • Findings are opposite to those seen in the general population

 

Highlights

 

  • In contrast to studies in the general population, tallness was associated with higher premature mortality risk and shorter life spans in patients on dialysis.
  • The association was observed in white, Asian, and American Indian/Alaskan native patients, but not in black patients.
  • The overall paradoxical relationship between height and premature death was not explained by concurrent illness, socioeconomic status, or differences in care.
  • Approximately 2 million patients in the world receive dialysis treatments.

 

Washington, DC, USA (October 1, 2015) — Although tall people in the general population tend to live longer than shorter people, the opposite appears to be true for patients receiving dialysis. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), could provide valuable information for kidney specialists.


Patients with kidney failure who are on dialysis have life spans that may be one-fifth that of the general population, and it is important to identify individual patient characteristics that are associated with longer survival. While studies in the general population have shown that taller individuals tend to live longer, few studies have described the relationship between adult height and survival in patients undergoing dialysis in the United States.

 

By analyzing data on 1, 171,842 patients who began dialysis in the United States from 1995 to 2008 were followed for an average for 1.6 years, Mohamed Elsayed, MD, John Ferguson, PhD, and Austin Stack, MD (University of Limerick, in Ireland) have now conducted the largest study to date on the relationship between height and premature mortality risk in dialysis patients.

 

Among the major findings:

 

  • In contrast to studies in the general population, tallness was associated with higher premature mortality risk and shorter life spans.
  • Overall, patients in the tallest categories had the highest risk of dying prematurely, although the association was stronger in men than in women, and the association was observed in white, Asian, and American Indian/Alaskan native patients, but not in black patients. (In fact, for black patients, increasing height was associated with a lower risk of premature death, as seen in the general population.)
  • This overall paradoxical relationship between height and premature death was not explained by concurrent illness, socioeconomic status, or differences in care provided to patients prior to or after initiating dialysis.
  • The duration of the dialysis treatment influenced the height-mortality association with higher mortality risks for taller patients who had received shorter treatment times.
  • The results also persisted when follow-up was extended to 5 years.

 

"Dialysis patients have extremely high premature death rates that are between 10- and 100-fold higher than in the general population, and height exerts an important quantifiable effect on dialysis patient survival. It is an easily measured physical trait and our study shows that it is an important prognostic marker for survival," said Dr. Stack. "As height is a component of body mass index, the relationship of body mass index with mortality in dialysis may be influenced by the prognostic contribution of height."

 

In an accompanying editorial, John Daugirdas, MD (University of Illinois, Chicago) notes that the results are intriguing, but "at this point, it is not at all clear what the physiology of increased mortality risk associated with taller stature might be, nor how this new knowledge might affect clinical practice."

 

 

Disclosures: Dr. Stack and Dr. Ferguson are supported by grants from the Irish Heart Foundation and the Health Research Board of Ireland. Dr Stack has consulted for Amgen, Abbott and AstraZeneca and has an investigator-initiated grant from Abbott.

 

The article, entitled "Association of Height with Elevated Mortality Risk in ESRD: Variation by Race and Gender," will appear online at http://jasn.asnjournals.org/ on October 1, 2015.

 

The editorial, entitled "You’re Not Big–You’re Just Tall, That’s All!" will appear online at http://jasn.asnjournals.org/ on October 1, 2015.

 

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

 

Founded in 1966, and with more than 15,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

 


American Society of Nephrology, 01.10.2015 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…